Secondary efficacy results from a phase 3 study comparing efficacy and safety of biosimilar candidate ABP 215 with bevacizumab in patients with non-squamous non-small cell lung cancer (NSCLC) - Thatcher, Nicholas; Thomas, Michael (Annals of oncology, 2016)
Gesehen am 14.11.2017